24 participants
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-09-04
- Start Date:
- 2012-08-31
- Completion:
- 2018-05-29
Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Mantle Cell Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Mantle Cell Lymphoma
Interventions
- DRUG
- OTHER
- BIOLOGICAL
No Results Yet